XML 17 R7.htm IDEA: XBRL DOCUMENT v3.25.2
Consolidated Statements of Shareholders' Equity - USD ($)
$ in Thousands
Total
Cumulative Effect, Period of Adoption, Adjustment
Common Stock
Retained Earnings
Retained Earnings
Cumulative Effect, Period of Adoption, Adjustment
Accumulated Other Compre-hensive Income (Loss)
Balance at beginning of period (in shares) at Sep. 30, 2023     8,105,338      
Balance at beginning of period at Sep. 30, 2023 $ 233,073   $ 34,771 $ 199,386   $ (1,084)
Increase (Decrease) in Stockholders' Equity [Roll Forward]            
Net income 17,928     17,928    
Other comprehensive income 539         539
Repurchase of common stock (in shares)     (182,117)      
Repurchase of common stock, net of tax $ (4,801)   $ (4,801)      
Exercise of stock options (in shares) 30,200   30,200      
Exercise of stock options $ 395   $ 395      
Common stock dividends (5,739)     (5,739)    
Stock-based compensation expense 316   $ 316      
Balance at end of period (in shares) at Jun. 30, 2024     7,953,421      
Balance at end of period at Jun. 30, 2024 241,223 $ (488) $ 30,681 211,087 $ (488) (545)
Balance at beginning of period (in shares) at Mar. 31, 2024     8,023,121      
Balance at beginning of period at Mar. 31, 2024 238,679   $ 32,338 207,086   (745)
Increase (Decrease) in Stockholders' Equity [Roll Forward]            
Net income 5,924     5,924    
Other comprehensive income 200         200
Repurchase of common stock (in shares)     (70,000)      
Repurchase of common stock, net of tax (1,767)   $ (1,767)      
Exercise of stock options (in shares)     300      
Exercise of stock options 5   $ 5      
Common stock dividends (1,923)     (1,923)    
Stock-based compensation expense 105   $ 105      
Balance at end of period (in shares) at Jun. 30, 2024     7,953,421      
Balance at end of period at Jun. 30, 2024 241,223 $ (488) $ 30,681 211,087 $ (488) (545)
Balance at beginning of period (in shares) at Sep. 30, 2024     7,960,127      
Balance at beginning of period at Sep. 30, 2024 245,413 [1]   $ 29,862 215,531   20
Increase (Decrease) in Stockholders' Equity [Roll Forward]            
Net income 20,715     20,715    
Other comprehensive income (795)         (795)
Repurchase of common stock (in shares)     (123,404)      
Repurchase of common stock, net of tax (3,846)   $ (3,846)      
Restricted Stock Grants Forfeitures (in shares)     (1,830)      
Restricted stock grant forfeitures $ (11)   $ (11)      
Exercise of stock options (in shares) 41,960   41,960      
Exercise of stock options $ 817   $ 817      
Common stock dividends (6,033)     (6,033)    
Stock-based compensation expense 404   $ 404      
Balance at end of period (in shares) at Jun. 30, 2025     7,876,853      
Balance at end of period at Jun. 30, 2025 256,664   $ 27,226 230,213   (775)
Balance at beginning of period (in shares) at Mar. 31, 2025     7,903,489      
Balance at beginning of period at Mar. 31, 2025 252,524   $ 28,028 225,166   (670)
Increase (Decrease) in Stockholders' Equity [Roll Forward]            
Net income 7,100     7,100    
Other comprehensive income (105)         (105)
Repurchase of common stock (in shares)     (34,236)      
Repurchase of common stock, net of tax (1,053)   $ (1,053)      
Exercise of stock options (in shares)     7,600      
Exercise of stock options 130   $ 130      
Common stock dividends (2,053)     (2,053)    
Stock-based compensation expense 121   $ 121      
Balance at end of period (in shares) at Jun. 30, 2025     7,876,853      
Balance at end of period at Jun. 30, 2025 $ 256,664   $ 27,226 $ 230,213   $ (775)
[1] Derived from audited consolidated financial statements.